IP Library › Granted Patent US 8,741,649
Granted Patent B2
US 8,741,649 · App. 13/393,456 · Granted Jun 3, 2014

Methods for enhancing genome stability and telomere elongation in embryonic stem cells

Inventors: Minoru S. H. Ko (Cockeysville, MD); Michal Zalzman (Baltimore, MD); Lioudmila V. Sharova (Pasadena, MD)
Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
C12N5/0606C12N15/00C12N5/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,741,649
App. No.
13/393,456
Granted
Jun 3, 2014
Kind
B2
Abstract

The disclosure provides methods for increasing genome stability of an embryonic stem (ES) cell or induced pluripotent stem (iPS) cell, increasing telomere length in an ES or iPS cell, or both, for example by contacting an ES or iPS cell with an agent that increases expression of Zscan4 in the cell. Methods for increasing the genome stability in a population of ES or iPS cells, increasing telomere length in a population of ES or iPS cells, or both, are provided, for example by selecting Zscan4 + ES or iPS cells from the population of ES or iPS cells (which can include both Zscan4 + and Zscan4 − ES or iPS cells). Therapeutic methods of using ES or iPS cells expressing Zscan4 are also provided. Further provided are methods of treating cancer by administering a Zscan4 polynucleotide or Zscan4 polypeptide. Also provided are methods of inducing differentiation of isolated ES or iPS cells into germ cells.

Claims (12)

1. A method for increasing genome stability of an isolated mouse embryonic stem (ES) cell; or increasing telomere length in an isolated mouse ES cell; or both, comprising transfecting an isolated nucleic acid molecule encoding mouse Zscan4c into the ES cell under conditions sufficient to allow for expression of mouse Zscan4c in the ES cell.

2. The method of claim 1 , wherein the isolated nucleic acid molecule comprises a vector.

3. The method of claim 2 , wherein the vector encodes mouse Zscan4c operably linked to a promoter.

4. The method of claim 1 , wherein the nucleotide sequence of mouse Zscan4c is at least 95% identical to the nucleotide sequence of SEQ ID NO: 28.

5. The method of claim 1 , wherein the nucleotide sequence of mouse Zscan4c comprises the nucleotide sequence of SEQ ID NO: 28.

6. The method of claim 1 , wherein the nucleotide sequence of mouse Zscan4c consists of the nucleotide sequence of SEQ ID NO: 28.

7. The method of claim 2 , wherein the vector is a viral vector.

8. The method of claim 2 , wherein the vector is a plasmid vector.

9. The method of claim 3 , wherein the promoter is a constitutive promoter.

10. The method of claim 3 , wherein the promoter is an inducible promoter.

11. The method of claim 1 , wherein expression of mouse Zscan4c is transient.

12. The method of claim 1 , wherein the isolated nucleic acid molecule encoding mouse Zscan4c is integrated into the genome of the ES cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2012
From: KO, MINORU S.H.; ZALZMAN, MICHAL; SHAROVA, LIOUDMILA V.
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 027841/0657 →
Continuity (2)
Provisional Application 61275983 · Sep 4, 2009
Related Publication 20120156305A1 · Jun 21, 2012